Terms: = Pancreatic cancer AND HSP90AA1, ENSG00000080824, 3320, P07900, LAP2, HSPN, HSPCAL4, HSPCAL1, HSPCA, HSPC1, HSP90N, HSP90A, Hsp90, Hsp89, HSP86, FLJ31884 AND Treatment
46 results:
1. Single-cell RNA-seq analyses inform necroptosis-associated myeloid lineages influence the immune landscape of pancreas cancer.
Dong W; Zhao H; Xiao S; Zheng L; Fan T; Wang L; Zhang H; Hu Y; Yang J; Wang T; Xiao W
Front Immunol; 2023; 14():1263633. PubMed ID: 38149248
[TBL] [Abstract] [Full Text] [Related]
2. Exploring dual effects of dinutuximab beta on cell death and proliferation of insulinoma.
Karatug Kacar A
Chem Biol Drug Des; 2024 Jan; 103(1):e14368. PubMed ID: 37802653
[TBL] [Abstract] [Full Text] [Related]
3. The therapeutic effects of exosomes the first time isolated from pancreatic islet-derived progenitor cells in the treatment of pancreatic cancer.
Hasoglu I; Karatug Kacar A
Protoplasma; 2024 Mar; 261(2):281-291. PubMed ID: 37798610
[TBL] [Abstract] [Full Text] [Related]
4. Promising targetable biomarkers in pancreatic neuroendocrine tumours.
Borghesani M; Gervaso L; Cella CA; Benini L; Ciardiello D; Algeri L; Ferrero A; Valenza C; Guidi L; Zampino MG; Spada F; Fazio N
Expert Rev Endocrinol Metab; 2023; 18(5):387-398. PubMed ID: 37743651
[TBL] [Abstract] [Full Text] [Related]
5. Targeting proteostasis of the HEV replicase to combat infection in preclinical models.
Zhang F; Xu LD; Zhang Q; Wang A; Yu X; Liu S; Chen C; Wu S; Jin J; Lin A; Neculai D; Zhao B; Feng XH; Liang T; Xu P; Huang YW
J Hepatol; 2023 Apr; 78(4):704-716. PubMed ID: 36574921
[TBL] [Abstract] [Full Text] [Related]
6. hsp90 inhibition acts synergistically with heat to induce a pro-immunogenic form of cell death in colon cancer cells.
Mouratidis PXE; Ter Haar G
Int J Hyperthermia; 2021; 38(1):1443-1456. PubMed ID: 34612127
[TBL] [Abstract] [Full Text] [Related]
7. Hypochlorous acid selectively promotes toxicity and the expression of danger signals in human abdominal cancer cells.
Freund E; Miebach L; Stope MB; Bekeschus S
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760187
[TBL] [Abstract] [Full Text] [Related]
8. Unbiased in vivo preclinical evaluation of anticancer drugs identifies effective therapy for the treatment of pancreatic adenocarcinoma.
Grbovic-Huezo O; Pitter KL; Lecomte N; Saglimbeni J; Askan G; Holm M; Melchor JP; Chandwani R; Joshi S; Haglund C; Iacobuzio-Donahue CA; Chiosis G; Tammela T; Leach SD
Proc Natl Acad Sci U S A; 2020 Dec; 117(48):30670-30678. PubMed ID: 33199632
[TBL] [Abstract] [Full Text] [Related]
9. Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes pancreatic Tumors to Proteotoxic Stress.
Tomihara H; Carbone F; Perelli L; Huang JK; Soeung M; Rose JL; Robinson FS; Lissanu Deribe Y; Feng N; Takeda M; Inoue A; Poggetto ED; Deem AK; Maitra A; Msaouel P; Tannir NM; Draetta GF; Viale A; Heffernan TP; Bristow CA; Carugo A; Genovese G
Cancer Res; 2021 Jan; 81(2):332-343. PubMed ID: 33158812
[TBL] [Abstract] [Full Text] [Related]
10. Heat Shock Protein-90 Inhibition Alters Activation of pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in pancreatic cancer.
Zhang Y; Ware MB; Zaidi MY; Ruggieri AN; Olson BM; Komar H; Farren MR; Nagaraju GP; Zhang C; Chen Z; Sarmiento JM; Ahmed R; Maithel SK; El-Rayes BF; Lesinski GB
Mol Cancer Ther; 2021 Jan; 20(1):150-160. PubMed ID: 33037138
[TBL] [Abstract] [Full Text] [Related]
11. Low-Dose hsp90 Inhibitor Selectively Radiosensitizes HNSCC and pancreatic Xenografts.
Mehta RK; Pal S; Kondapi K; Sitto M; Dewar C; Devasia T; Schipper MJ; Thomas DG; Basrur V; Pai MP; Morishima Y; Osawa Y; Pratt WB; Lawrence TS; Nyati MK
Clin Cancer Res; 2020 Oct; 26(19):5246-5257. PubMed ID: 32718999
[TBL] [Abstract] [Full Text] [Related]
12. Defining and Targeting Adaptations to Oncogenic KRAS
Santana-Codina N; Chandhoke AS; Yu Q; Małachowska B; Kuljanin M; Gikandi A; Stańczak M; Gableske S; Jedrychowski MP; Scott DA; Aguirre AJ; Fendler W; Gray NS; Mancias JD
Cell Rep; 2020 Mar; 30(13):4584-4599.e4. PubMed ID: 32234489
[TBL] [Abstract] [Full Text] [Related]
13. Thioredoxin interacting protein (Txnip) forms redox sensitive high molecular weight nucleoprotein complexes.
Hirata CL; Ito S; Masutani H
Arch Biochem Biophys; 2019 Nov; 677():108159. PubMed ID: 31669268
[TBL] [Abstract] [Full Text] [Related]
14. First-in-Human Phase I Study of an Oral hsp90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.
Shimomura A; Yamamoto N; Kondo S; Fujiwara Y; Suzuki S; Yanagitani N; Horiike A; Kitazono S; Ohyanagi F; Doi T; Kuboki Y; Kawazoe A; Shitara K; Ohno I; Banerji U; Sundar R; Ohkubo S; Calleja EM; Nishio M
Mol Cancer Ther; 2019 Mar; 18(3):531-540. PubMed ID: 30679388
[TBL] [Abstract] [Full Text] [Related]
15. Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant cancers.
Gay CM; Tong P; Cardnell RJ; Sen T; Su X; Ma J; Bara RO; Johnson FM; Wakefield C; Heymach JV; Wang J; Byers LA
Clin Cancer Res; 2019 Jan; 25(1):346-357. PubMed ID: 30257981
[TBL] [Abstract] [Full Text] [Related]
16. PRDM14 directly interacts with heat shock proteins hsp90α and glucose-regulated protein 78.
Moriya C; Taniguchi H; Nagatoishi S; Igarashi H; Tsumoto K; Imai K
Cancer Sci; 2018 Feb; 109(2):373-383. PubMed ID: 29178343
[TBL] [Abstract] [Full Text] [Related]
17. Inhibiting heat shock protein 90 and the ubiquitin-proteasome pathway impairs metabolic homeostasis and leads to cell death in human pancreatic cancer cells.
Belalcazar A; Shaib WL; Farren MR; Zhang C; Chen Z; Yang L; Lesinski GB; El-Rayes BF; Nagaraju GP
Cancer; 2017 Dec; 123(24):4924-4933. PubMed ID: 28841232
[TBL] [Abstract] [Full Text] [Related]
18. [pancreatic acinar neoplasms : Comparative molecular characterization].
Bergmann F
Pathologe; 2016 Nov; 37(Suppl 2):191-195. PubMed ID: 27807633
[TBL] [Abstract] [Full Text] [Related]
19. Targeted delivery of chemotherapy using hsp90 inhibitor drug conjugates is highly active against pancreatic cancer models.
Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
[TBL] [Abstract] [Full Text] [Related]
20. A phase II study of the hsp90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer.
Renouf DJ; Hedley D; Krzyzanowska MK; Schmuck M; Wang L; Moore MJ
Cancer Chemother Pharmacol; 2016 Sep; 78(3):541-5. PubMed ID: 27422303
[TBL] [Abstract] [Full Text] [Related]
[Next]
